Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and PK of FB825 in Healthy Volunteers
NCT02309762Phase 1Completed
- Sponsor
- Fountain Biopharma Inc.
- Start
- Mar 2015
- Primary completion
- Feb 2016
- Modality
- Monoclonal Antibodies
01
Overview
Phase 1, randomised, double-blind trial in atopic dermatitis (AD) and allergic asthma comparing FB825 with Placebo (2 arms). Primary endpoints: Number of Participants with Adverse events (AE), Clinical laboratory test results and 3 more. Started Mar 2015; status: completed.
02
Drugs
FB825
03
Conditions
atopic dermatitis (AD)allergic asthma
Beyond the preview
Go deeper on NCT02309762.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02309762.